[시장보고서]제제 개발 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 제제별, 치료 영역별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

제제 개발 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 제제별, 치료 영역별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Formulation Development Outsourcing Market Size, Share & Trends Analysis Report By Service (Preformulation, Formulation Development), By Formulation, By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2025 - 2030

상품코드 : 1726208

리서치사 : Grand View Research, Inc.

발행일 : 2025년 04월

페이지 정보 : 영문 120 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,152,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 9,522,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,262,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

제제 개발 아웃소싱 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 제제 개발 아웃소싱 시장 규모는 2030년까지 606억 6,000만 달러에 이르며, 2025-2030년 CAGR은 8.62%를 나타낼 것으로 추정됩니다.

만성 질환과 감염증에 대한 높은 부담, 난용성 약제의 생체이용률 개선에 대한 관심이 높아지고, 약제 개발에 따른 합병증 등이 제제 개발 서비스의 세계의 수요에 기여하고 있습니다. 바이러스에 대한 효과적인 치료법을 찾는 임상 검사의 필요성에 영향을 미치고 있습니다.

Pharma R&D Annual Review 2022에 따르면, 2022년에 개발 단계에 있는 주요 의약품은 바이오 의약품과 항암제였으며, 이것에 의해 팬데믹 후의 이러한 의약품의 제제 개발 수요가 향상했습니다. 예를 들어, 머크의 2020년 R&D 비용은 25억 1,680만 달러로 2019년의 24억 9,480만 달러에 비해 크게 증가했습니다.

제제 개발에 수반되는 합병증에 의해 후기 임상 검사에 이르지 않는 의약품은 상당수에 오릅니다. 또한, 의약품의 개발에 관한 엄격한 규제가, 제제 개발의 아웃소싱 수요를 한층 더 높여지고 있습니다. COVID-19의 발병률은 세계의 백신 접종의 활성화로 인해 크게 감소하고 있습니다. 예를 들어, 랩코프는 2022년 4월 엑셀 바이오사이언스와 협력하여 암, 파킨슨병 및 기타 희귀 질환 치료를 위한 세포 및 유전자 치료법을 개발하는 회사를 지원한 바 있습니다.

제제 개발 아웃소싱 시장 보고서 하이라이트

서비스별로는 프리포뮬레이션 부문이 예측기간 중에 가장 빠른 CAGR을 나타낼 것으로 예측됩니다.
제제 부문에서는 예측 기간 중에 상당한 CAGR을 나타내 대폭적인 성장이 예상됩니다.
치료 영역별로는 암 영역이 2024년에 최대 시장 수익 점유율을 차지했습니다.
아시아태평양은 비용 효율적인 제제 개발 서비스를 제공하는 CRO가 다수 존재하기 때문에 2024년에 최대의 수익 점유율을 차지했습니다.

시장 계통의 전망
- 모 시장 전망
- 관련/보조시장 전망
시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
임상 검사 건수 분석(2024년)
- 지역별 임상 검사 총수
- 임상 검사의 총수(상별)
- 임상 검사의 총수(연구 디자인별)
- 주요 치료 영역별 임상 검사 총수
가격 모델 분석
기술
시장 분석 도구
- Porter's Five Forces 분석
- SWOT 분석에 의한 PESTEL
- COVID-19의 영향 분석

제4장 제제 개발 아웃소싱 시장 : 서비스별, 추정 및 동향 분석

제제 개발 아웃소싱 시장(서비스별) : 부문 대시보드
제제 개발 아웃소싱 시장(서비스별) : 변동 분석
서비스별(2018-2030년)
프리포뮬레이션
제제 개발

제5장 제제 개발 아웃소싱 시장 : 제제별, 추정 및 동향 분석

제제 개발 아웃소싱 시장(제제별) : 부문 대시보드
제제 개발 아웃소싱 시장(제제별) : 변동 분석
제제별(2018-2030년)
경구
주사제
국소
기타

제6장 제제 개발 아웃소싱 시장 : 치료 영역별, 추정 및 동향 분석

제제 개발 아웃소싱 시장(치료 영역별) : 부문 대시보드
제제 개발 아웃소싱 시장(치료 영역별) : 변동 분석
치료 영역별(2018-2030년)
종양학
전염병
신경학
혈액학
호흡기
심혈관
피부과
기타

제7장 제제 개발 아웃소싱 시장 : 최종 용도별, 추정 및 동향 분석

제제 개발 아웃소싱 시장(최종 용도별) : 부문 대시보드
제제 개발 아웃소싱 시장(최종 용도별) : 변동 분석
최종 용도별(2018-2030년)
제약 및 생명공학 회사
정부 및 학술기관
기타

제8장 제제 개발 아웃소싱 시장 : 지역별, 추정 및 동향 분석

지역별 시장 점유율 분석(2024년, 2030년)
지역별 시장 대시보드
세계의 지역 시장 현황
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 스위스
- 스웨덴
- 덴마크
- 노르웨이
아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- 인도네시아
- 말레이시아
- 싱가포르
- 태국
- 대만
라틴아메리카
- 브라질
- 아르헨티나
- 콜롬비아
- 칠레
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 이집트
- 이스라엘
- 쿠웨이트

제9장 경쟁 구도

시장 진출기업의 분류
기업의 시장 점유율/평가 분석(2024년)
기업 프로파일
- SGS SA
- Intertek Group plc
- Recipharm
- Lonza
- Charles River Laboratories International, Inc.
- Eurofins Scientific SE
- Element
- Labcorp
- Thermo Fisher Scientific, Inc.
- Catalent Inc.

제10장 주요 권장사항

KTH

영문 목차

영문목차

Formulation Development Outsourcing Market Growth & Trends:

The global formulation development outsourcing market size is estimated to reach USD 60.66 billion by 2030, registering a CAGR of 8.62% from 2025 to 2030, according to a new report by Grand View Research, Inc. The high burden of chronic and infectious diseases, the growing focus on improving the bioavailability of poorly soluble drugs, and the complications associated with drug development are contributing to the demand for formulation development services globally. Furthermore, the COVID-19 outbreak has influenced the need for clinical trials to find an effective treatment against the contagious virus. This has resulted in significant investments in research and development (R&D) to develop therapeutics, which are expected to drive the market.

According to Pharma R&D Annual Review 2022, biopharmaceutical and anticancer drugs are the major drugs in the development stage in the year 2022, this is expected to improve the demand for formulation development of these drugs post-pandemic. Globally, the pharmaceutical companies are making significant contributions to R&D activities. For instance, Merck's R&D cost was USD 2,516.8 million in 2020 as compared to USD 2,494.8 million in 2019. Similarly, Biogen's R&D expenses accounted for USD 3,990.9 million in 2020. The company's R&D expenditure increased by 75% as compared to 2019. The significant increase in R&D expenditure is likely to have a positive impact on the market.

A significant number of drugs fail to reach late-stage clinical trials owing to complications associated with formulation development. Moreover, strict regulations regarding the development of drugs are further contributing to the demand for outsourcing formulation development. Such factors are expected to improve the demand. The COVID-19 incidence has been significantly reduced owing to the growing vaccination drive globally. As a result, the CRO and CDMO are once again concentrating on the development of drugs for oncology and other disorders. For instance, in April 2022, Labcorp collaborated with Xcell Biosciences to support the company in developing cell and gene therapies for treating cancer, Parkinson's disease, and other rare diseases. Such initiatives by the CDMOs are likely to promote the demand for the formulation development outsourcing of drugs used in the treatment of cancer and other rare diseases.

Formulation Development Outsourcing Market Report Highlights:

Based on services, the preformulation segment is expected to grow at the fastest CAGR during the forecast period.
Based on formulation, the drug product segment is expected to grow at a significant CAGR during the forecast period.
Based on therapeutic area, the oncology segment accounted for the largest market revenue share in 2024.
Asia Pacific held the largest revenue share in 2024, due to the presence of a significant number of CROs providing cost effective formulation development services.

Chapter 1. Research Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Service
- 1.2.2. Formulation
- 1.2.3. Therapeutic Area
- 1.2.4. End Use
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.7.2. Parent Market Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Formulation Development Outsourcing Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Clinical Trials Volume Analysis, (2024)
- 3.3.1. Total Number of Clinical Trials By Region
- 3.3.2. Total Number of Clinical Trials, By Phase
- 3.3.3. Total Number of Clinical Trials, By Study Design
- 3.3.4. Total Number of Clinical Trials, By Key Therapeutic Area
3.4. Pricing Model Analysis
3.5. Technology Landscape
3.6. Market Analysis Tools
- 3.6.1. Porter's Five Force Analysis
- 3.6.2. PESTEL by SWOT Analysis
- 3.6.3. COVID-19 Impact Analysis

Chapter 4. Formulation Development Outsourcing Market: Service Estimates & Trend Analysis

4.1. Formulation Development Outsourcing Market, By Service: Segment Dashboard
4.2. Formulation Development Outsourcing Market, By Service: Movement Analysis
4.3. Formulation Development Outsourcing Market Estimates & Forecasts, By Service, 2018 - 2030
4.4. Preformulation
- 4.4.1. Preformulation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Formulation Development
- 4.5.1. Formulation Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Formulation Development Outsourcing Market: Formulation Estimates & Trend Analysis

5.1. Formulation Development Outsourcing Market, By Formulation: Segment Dashboard
5.2. Formulation Development Outsourcing Market, By Formulation: Movement Analysis
5.3. Formulation Development Outsourcing Market Estimates & Forecasts, By Formulation, 2018 - 2030
5.4. Oral
- 5.4.1. Oral Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Injectable
- 5.5.1. Injectable Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Topical
- 5.6.1. Topical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Others
- 5.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Formulation Development Outsourcing Market: Therapeutic Area Estimates & Trend Analysis

6.1. Formulation Development Outsourcing Market, By Therapeutic Area: Segment Dashboard
6.2. Formulation Development Outsourcing Market, By Therapeutic Area: Movement Analysis
6.3. Formulation Development Outsourcing Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
6.4. Oncology
- 6.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Infectious Disease
- 6.5.1. Infectious Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Neurology
- 6.6.1. Neurology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Hematology
- 6.7.1. Hematology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Respiratory
- 6.8.1. Respiratory Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.9. Cardiovascular
- 6.9.1. Cardiovascular Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.10. Dermatology
- 6.10.1. Dermatology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.11. Others
- 6.11.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Formulation Development Outsourcing Market: End Use Estimates & Trend Analysis

7.1. Formulation Development Outsourcing Market, By End Use: Segment Dashboard
7.2. Formulation Development Outsourcing Market, By End Use: Movement Analysis
7.3. Formulation Development Outsourcing Market Estimates & Forecasts, By End Use, 2018 - 2030
7.4. Pharmaceutical and Biopharmaceutical Companies
- 7.4.1. Pharmaceutical and Biopharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Government and Academic Institutes
- 7.5.1. Government and Academic Institutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Others
- 7.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Formulation Development Outsourcing Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. North America
- 8.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. U.S
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Competitive Scenario
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Canada
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Competitive Scenario
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. Mexico
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Competitive Scenario
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
- 8.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Competitive Scenario
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Germany
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Competitive Scenario
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.4. France
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Competitive Scenario
  - 8.5.4.3. Regulatory Framework
  - 8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.5. Italy
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Competitive Scenario
  - 8.5.5.3. Regulatory Framework
  - 8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.6. Spain
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Competitive Scenario
  - 8.5.6.3. Regulatory Framework
  - 8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.7. Netherlands
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. Competitive Scenario
  - 8.5.7.3. Regulatory Framework
  - 8.5.7.4. Netherlands Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.8. Switzerland
  - 8.5.8.1. Key Country Dynamics
  - 8.5.8.2. Competitive Scenario
  - 8.5.8.3. Regulatory Framework
  - 8.5.8.4. Switzerland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.9. Sweden
  - 8.5.9.1. Key Country Dynamics
  - 8.5.9.2. Competitive Scenario
  - 8.5.9.3. Regulatory Framework
  - 8.5.9.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.10. Denmark
  - 8.5.10.1. Key Country Dynamics
  - 8.5.10.2. Competitive Scenario
  - 8.5.10.3. Regulatory Framework
  - 8.5.10.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.11. Norway
  - 8.5.11.1. Key Country Dynamics
  - 8.5.11.2. Competitive Scenario
  - 8.5.11.3. Regulatory Framework
  - 8.5.11.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
- 8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. China
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Competitive Scenario
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. India
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Competitive Scenario
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. Japan
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Competitive Scenario
  - 8.6.4.3. Regulatory Framework
  - 8.6.4.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Australia
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Competitive Scenario
  - 8.6.5.3. Regulatory Framework
  - 8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.6. South Korea
  - 8.6.6.1. Key Country Dynamics
  - 8.6.6.2. Competitive Scenario
  - 8.6.6.3. Regulatory Framework
  - 8.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.7. Indonesia
  - 8.6.7.1. Key Country Dynamics
  - 8.6.7.2. Competitive Scenario
  - 8.6.7.3. Regulatory Framework
  - 8.6.7.4. Indonesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.8. Malaysia
  - 8.6.8.1. Key Country Dynamics
  - 8.6.8.2. Competitive Scenario
  - 8.6.8.3. Regulatory Framework
  - 8.6.8.4. Malaysia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.9. Singapore
  - 8.6.9.1. Key Country Dynamics
  - 8.6.9.2. Competitive Scenario
  - 8.6.9.3. Regulatory Framework
  - 8.6.9.4. Singapore Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.10. Thailand
  - 8.6.10.1. Key Country Dynamics
  - 8.6.10.2. Competitive Scenario
  - 8.6.10.3. Regulatory Framework
  - 8.6.10.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.11. Taiwan
  - 8.6.11.1. Key Country Dynamics
  - 8.6.11.2. Competitive Scenario
  - 8.6.11.3. Regulatory Framework
  - 8.6.11.4. Taiwan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
- 8.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. Competitive Scenario
  - 8.7.2.3. Regulatory Framework
  - 8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. Competitive Scenario
  - 8.7.3.3. Regulatory Framework
  - 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.4. Colombia
  - 8.7.4.1. Key Country Dynamics
  - 8.7.4.2. Competitive Scenario
  - 8.7.4.3. Regulatory Framework
  - 8.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.5. Chile
  - 8.7.5.1. Key Country Dynamics
  - 8.7.5.2. Competitive Scenario
  - 8.7.5.3. Regulatory Framework
  - 8.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8. MEA
- 8.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key Country Dynamics
  - 8.8.2.2. Competitive Scenario
  - 8.8.2.3. Regulatory Framework
  - 8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key Country Dynamics
  - 8.8.3.2. Competitive Scenario
  - 8.8.3.3. Regulatory Framework
  - 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key Country Dynamics
  - 8.8.4.2. Competitive Scenario
  - 8.8.4.3. Regulatory Framework
  - 8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.5. Egypt
  - 8.8.5.1. Key Country Dynamics
  - 8.8.5.2. Competitive Scenario
  - 8.8.5.3. Regulatory Framework
  - 8.8.5.4. Egypt Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.6. Israel
  - 8.8.6.1. Key Country Dynamics
  - 8.8.6.2. Competitive Scenario
  - 8.8.6.3. Regulatory Framework
  - 8.8.6.4. Israel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.7. Kuwait
  - 8.8.7.1. Key Country Dynamics
  - 8.8.7.2. Competitive Scenario
  - 8.8.7.3. Regulatory Framework
  - 8.8.7.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Market Participant Categorization
9.2. Company Market Share/Assessment Analysis, 2024
9.3. Company Profiles
- 9.3.1. SGS S.A.
  - 9.3.1.1. Company Overview
  - 9.3.1.2. Financial Performance
  - 9.3.1.3. Service Benchmarking
  - 9.3.1.4. Strategic Initiatives
- 9.3.2. Intertek Group plc
  - 9.3.2.1. Company Overview
  - 9.3.2.2. Financial Performance
  - 9.3.2.3. Service Benchmarking
  - 9.3.2.4. Strategic Initiatives
- 9.3.3. Recipharm
  - 9.3.3.1. Company Overview
  - 9.3.3.2. Financial Performance
  - 9.3.3.3. Service Benchmarking
  - 9.3.3.4. Strategic Initiatives
- 9.3.4. Lonza
  - 9.3.4.1. Company Overview
  - 9.3.4.2. Financial Performance
  - 9.3.4.3. Service Benchmarking
  - 9.3.4.4. Strategic Initiatives
- 9.3.5. Charles River Laboratories International, Inc.
  - 9.3.5.1. Company Overview
  - 9.3.5.2. Financial Performance
  - 9.3.5.3. Service Benchmarking
  - 9.3.5.4. Strategic Initiatives
- 9.3.6. Eurofins Scientific SE
  - 9.3.6.1. Company Overview
  - 9.3.6.2. Financial Performance
  - 9.3.6.3. Service Benchmarking
  - 9.3.6.4. Strategic Initiatives
- 9.3.7. Element
  - 9.3.7.1. Company Overview
  - 9.3.7.2. Financial Performance
  - 9.3.7.3. Service Benchmarking
  - 9.3.7.4. Strategic Initiatives
- 9.3.8. Labcorp
  - 9.3.8.1. Company Overview
  - 9.3.8.2. Financial Performance
  - 9.3.8.3. Service Benchmarking
  - 9.3.8.4. Strategic Initiatives
- 9.3.9. Thermo Fisher Scientific, Inc.
  - 9.3.9.1. Company Overview
  - 9.3.9.2. Financial Performance
  - 9.3.9.3. Service Benchmarking
  - 9.3.9.4. Strategic Initiatives
- 9.3.10. Catalent Inc.
  - 9.3.10.1. Company Overview
  - 9.3.10.2. Financial Performance
  - 9.3.10.3. Service Benchmarking
  - 9.3.10.4. Strategic Initiatives